Abstracts tagged "Myositis and pulmonary complications"

Abstract Number: 307 • 2015 ACR/ARHP Annual Meeting
Screening for Pulmonary Hypertension in the Anti-Synthetase Syndrome; Utility of Four Different Screening Approaches
Helena Andersson¹, Ivar Sjaastad², Thomas Schwartz², Torhild Garen³, T. Mogens Aalokken⁴ and Øyvind Molberg¹, ¹Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway, ²Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, ³Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Department of Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Pulmonary hypertension (PH) is a feared complication of the anti-synthetase syndrome (ASS) and has previously been reported to occur in 8% of the patients…
Abstract Number: 231 • 2012 ACR/ARHP Annual Meeting
Pulmonary Hypertension in the Antisynthetase Syndrome
Helena Andersson¹, T. Mogens Aalokken², Torhild Garen³, Oyvind Molberg⁴ and Jan Tore Gran¹, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁴Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Methods: Objectives: To describe the frequency and clinical characteristics of pulmonary hypertension (PH) in a cohort of Antisynthetase Syndrome (ASS) patients.Methods: Patients from a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].